Cotellic — CareFirst (Caremark)
Central nervous system cancers including gliomas, meningiomas, or astrocytomas that are BRAF V600 mutation-positive
Initial criteria
- Documentation of BRAF V600 mutation-positive (e.g., BRAF V600E or V600K)
- Used for treatment of glioma, meningioma, or astrocytoma
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months